|
|
|||||||
Multiple Myeloma |
All authors from department of Hematology, Changzheng Hospital, the second hospital affiliated to the Second Military Medical University, 415 Fengyang Rd., Shanghai 200003, PR China
Correspondence: Jian Hou, Department of Hematology, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Rd., Shanghai 200003, PR China. E-mail: houjian167{at}sohu.com
In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMs) was statistically higher than that of poor metabolizers (PMs) (62.6% vs. 33.3%, p<0.05). Similar results were also observed in the Thal+Dex cohort. For the first time, our primary data suggested that the polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in MM.
Key words: thalidomide, multiple myeloma, CYP2C19 genotype, efficacy.
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |